Research Report: CAR-Ma

I am excited to share my report on a novel CAR-Ma product for cancer immunotherapy, part of the HKU iGEM 2024 Team. This project enhances macrophage activity against solid tumors, addressing the limitations of current therapies in genomics and biotechnology. Hope you find valuable insights!
Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

The project employs cutting-edge techniques, including plasmid assembly, in vitro transcription, and electroporation into target cell lines, with preliminary results demonstrating successful plasmid verification and RNA synthesis.

CAR-Ma signifies a substantial leap forward in cancer immunotherapy, offering a cost-effective solution that enhances therapeutic efficacy while minimizing potential side effects. Its unique design not only improves treatment outcomes but also holds promise for broader applications in precision medicine. 

Please sign in

If you are a registered user on Laidlaw Scholars Network, please sign in